abstract |
Abstract This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and osteoblastic bone metastases, with a dual inhibitor of MET and VEGF. WO 2012/044572 PCT/US201 1/053233 Patient 3 Baseline Week 6 Week 12 B 200 1 a AP 20 S16,20. S 0 -2 0 24 8 10 12 14 16 18 20 Weeks on Study |